LIPO — Lipella Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $6.41m
- $4.23m
- $0.54m
Annual income statement for Lipella Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.962 | 0.259 | 0.184 | 0.45 | 0.536 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 1.02 | 2.18 | 2.77 | 5.2 | 5.62 |
| Operating Profit | -0.057 | -1.92 | -2.59 | -4.75 | -5.08 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.062 | -1.87 | -2.6 | -4.62 | -5.02 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.062 | -1.87 | -2.6 | -4.62 | -5.02 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.062 | -1.87 | -2.6 | -4.62 | -5.02 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -0.062 | -1.87 | -2.6 | -4.62 | -5.02 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.086 | -2.6 | -5.12 | -6.16 | -4.79 |
| Dividends per Share |